Pulmatrix, Inc.
PULMNasdaq
$1.69
↑ +5.0%Jul 17 close · end-of-day
Price
1Y↓ -72.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$6.2M
Enterprise Value
$2.8M
P/E
—
P/S
—
P/B
1.7
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$4.5M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-126.0%
ROIC
-1365.2%
Debt / Equity
—
Net Cash
$3.3M
Return 1Y
-73.3%
Company profile
Pulmatrix, Inc. discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology. Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis, and in patients with cystic fibrosis, is in Phase 1b clinical trials.
- CEO
- Teofilo Raad
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- Massachusetts
- Website
- pulmatrix.com
Earnings
PULM Q 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.32↓ -36.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $12.6M | $5.2M | $6.1M | $7.3M | $7.8M | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$9.9M | -$20.2M | -$18.9M | -$14.7M | -$9.8M | -$5.2M |
| Net income | -$19.3M | -$20.2M | -$18.8M | -$14.1M | -$9.6M | -$5.2M |
| Diluted EPS | — | — | -$5.46 | -$3.87 | -$2.62 | -$1.41 |
| Operating cash flow | -$12.5M | -$19.7M | -$19.4M | -$16.0M | -$10.7M | -$5.4M |
| Free cash flow | -$12.8M | -$19.9M | -$19.4M | -$16.7M | -$11.1M | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -78.1% | -390.2% | -312.1% | -202.0% | -125.1% | — |
| Net margin | -152.8% | -390.2% | -310.3% | -193.5% | -122.5% | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.6M | $366,000.00 | $3,000.00 | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$5.9M | -$2.7M | -$2.0M | -$1.8M | -$1.5M | -$866,000.00 | -$908,000.00 | -$1.3M |
| Net income | -$5.8M | -$2.6M | -$2.0M | -$1.8M | -$1.5M | -$877,000.00 | -$928,000.00 | -$1.2M |
| Diluted EPS | -$1.59 | -$0.71 | -$0.55 | -$0.50 | -$0.42 | -$0.24 | -$0.25 | -$0.32 |
| Operating cash flow | -$3.7M | -$3.1M | -$1.3M | -$1.8M | -$1.9M | -$1.0M | -$706,000.00 | -$1.1M |
| Free cash flow | -$3.9M | -$3.1M | -$1.3M | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -380.2% | -726.0% | -65066.7% | — | — | — | — | — |
| Net margin | -374.4% | -706.8% | -66200.0% | — | — | — | — | — |
Company news
Apr 21, 2026
Mar 26, 2026
Mar 3, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.